Expression of the cell-surface antigen CD10 has long been used to define the lymphoid commitment of human cells. Here we report a unique lymphoid-primed population in human bone marrow that was generated from hematopoietic stem cells (HSCs) before onset of the expression of CD10 and commitment to the B cell lineage. We identified this subset by high expression of the homing molecule L-selectin (CD62L). CD10 − CD62L hi progenitors had full lymphoid and monocytic potential but lacked erythroid potential. Gene-expression profiling placed the CD10 − CD62L hi population at an intermediate stage of differentiation between HSCs and lineage-negative (Lin − ) CD34 + CD10 + progenitors. CD62L was expressed on immature thymocytes, and its ligands were expressed at the cortico-medullary junction of the thymus, which suggested a possible role for this molecule in homing to the thymus. Our studies identify the earliest stage of lymphoid priming in human bone marrow. npg
A r t i c l e s
Although much is known about the identity of progenitor stages in mouse lymphopoiesis, considerably less is understood about the critical stages of lymphoid commitment of human hematopoietic cells. Early models developed from mouse studies assumed strictly dichotomous pathways of lineage commitment 1 . Those ideas have evolved into models of gradual loss of lineage potential that can occur via multiple alternative pathways, although the physiological relevance of lineage potential demonstrated in certain in vitro assays continues to be debated [2] [3] [4] [5] . A stage at which mouse bone marrow progenitors are 'lymphoid primed' before complete loss of myeloid potential has been defined on the basis of expression of the cell-surface receptor Flt3, and cells at this stage have been called 'lymphoid-primed multipotent progenitors' (LMPPs) 2 .
Critical species-specific differences create challenges for the 'translation' of knowledge about cellular hierarchies derived from mouse studies to the specifics of human hematopoiesis 6 . In addition, the source and stage in ontogeny of human hematopoiesis can influence the functional abilities, surface immunophenotypes and transcriptional profiles of the cells under study [6] [7] [8] . Most studies of the earliest progenitor stages of human hematopoiesis have used neonatal umbilical cord blood (UCB) as the source of hematopoietic cells. However, understanding how lymphopoiesis is regulated during steady-state adult hematopoiesis requires direct study of hematopoietic stem cells and progenitors from postnatal human bone marrow 8,9 . The stepwise process of the lymphoid differentiation of multipotent hematopoietic stem cells (HSCs) in human bone marrow has been assumed to begin with expression of the cell surface antigen CD10 (CALLA or MME) on CD34 + progenitors, based on the finding that CD10 + progenitors lack myeloid and erythroid potential but are able to generate all lymphoid lineages 10 . However, subsequent studies have shown that CD34 + CD10 + cells, even those without expression of lineage markers (Lin − : CD3 − CD14 − CD15 − CD19 − CD56 − CD235a − ), show a strong bias toward B cell potential with relatively little T cell or natural killer (NK) cell potential 11, 12 . CD34 + Lin − CD10 + cells that lack expression of CD24 are precursors of the CD34 + Lin − CD10 + CD24 + population but nonetheless show molecular evidence of commitment to the B cell lineage, with expression of several B cell-specific genes 12 . Therefore, to understand the progenitor hierarchy of the lymphoid commitment of human cells, we sought to identify a stage of lymphoid priming that precedes commitment to the B lymphoid lineage, either before or independently of CD10 expression.
L-selectin (CD62L) is expressed on lymphocytes and mediates homing to peripheral lymphoid organs 13 . Studies have reported that upregulation of CD62L expression on c-Kit + Lin − Sca-1 + mouse bone marrow cells correlates with loss of erythroid and megakaryocyte potential and efficient thymic engraftment [14] [15] [16] . In this study we have identified a CD34 + Lin − CD10 − progenitor subpopulation in human bone marrow that had high expression of CD62L and that was devoid of clonogenic myeloid or erythroid potential. In stromal cultures, these cells were able to generate B cells, NK cells and T cells, as well as monocytic and dendritic cells, similar to the LMPPs in mouse bone marrow that 9 6 4 VOLUME 13 NUMBER 10 OCTOBER 2012 nature immunology A r t i c l e s have been reported before 2 . CD34 + Lin − CD10 − CD62L hi cells (called 'CD10 − CD62L hi cells' here) rapidly engrafted immunodeficient mice, producing B cells and myeloid cells. Despite evidence of lymphoid skewing, comprehensive molecular analysis showed that CD10 − CD62L hi cells not only lacked B cell-specific transcripts but also had not initiated DNA recombination, as determined by their lack of expression of the recombinase component-encoding genes RAG1 and RAG2 and minimal expression of DNTT, which encodes terminal deoxynucleotidyltransferase. Genome-wide expression and functional analysis identified the CD10 − CD62L hi progenitor population as a developmental intermediate between the multipotent CD34 + Lin − CD38 − population and the CD34 + Lin − CD10 + lymphoid progenitor population.
We also found that primitive lymphoid-restricted CD34 + CD1a − progenitors in human thymus expressed CD62L and that the vasculature at the cortico-medullary junction of human thymus expressed ligands for CD62L, which suggested the possibility that CD62L may have a role in homing to the human thymus. We propose that the CD10 − CD62L hi progenitor in bone marrow represents the earliest stage at which adult human progenitors become lymphoid primed. The identification of this progenitor population will facilitate a more complete understanding of the regulation of the lymphoid commitment of HSCs during normal and aberrant human hematopoiesis.
RESULTS
The lymphoid marker CD7 does not define lymphoid commitment Given published reports linking expression of the lymphoid marker CD7 to early stages of lymphoid commitment in UCB [17] [18] [19] [20] , we first investigated whether expression of CD7 was sufficient to identify lymphoid commitment in human bone marrow independently of CD10 expression. Examination of CD34 + cell populations depleted of lineage marker-expressing cells showed that the CD34 + Lin − CD38 − CD7 + population identified before in UCB 17 was not detectable in human bone marrow ( Supplementary Fig. 1a ). However, as noted before 7 , we detected low expression of CD7 on a small population of CD34 + Lin − CD38 + human bone marrow cells (2.8% ± 0.6%; n = 5 donors), most of which did not coexpress CD10 ( Fig. 1a) . Clonogenic assays demonstrated that CD7 expression alone was insufficient to define lymphoid restriction of the CD34 + Lin − CD10 − population of bone marrow; nonlymphoid clonogenic cells, particularly erythroid progenitors, were readily detectable in the CD34 + Lin − CD10 − CD7 + population by assay of colony-forming unit cells (CFU-C; Fig. 1b) . Consistent with published studies of bone marrow and UCB 7,10-12,21 , CD34 + Lin − CD10 + progenitors were devoid of clonogenic myeloid or erythroid progenitors ( Fig. 1b) .
CD62L hi progenitors do not have CFU-C potential
The naive-cell marker CD45RA has been shown to be expressed on various lymphoid progenitors 10, [17] [18] [19] and granulocyte-macrophage progenitors 22 . Analysis of the CD34 + Lin − CD10 − subpopulation demonstrated the presence of both CD45RA − and CD45RA + fractions; in contrast, all CD34 + Lin − CD10 + cells were CD45RA + (Fig. 1c) . Erythroid potential was absent, but clonogenic myeloid progenitors were still readily detectable, by assay of CFU granulocytesmacrophages, in the CD34 + Lin − CD10 − CD45RA + population ( Fig. 1d) . As expected, clonogenic erythroid potential was high in megakarocytic-erythroid progenitors and common myeloid progenitors ( Fig. 1d) , neither of which express CD45RA.
Further refinement of the CD10 − CD45RA + population was needed to identify those cells that lacked clonogenic myeloid potential. As noted above, CD62L is a cell-surface receptor that mediates the homing of lymphocytes to peripheral lymph nodes 13 and is expressed on certain mouse bone marrow progenitors that lack erythroid or megakaryocytic potential 14 . Analysis of the CD34 + Lin − CD10 − CD45RA + population demonstrated that although most cells had low expression of CD62L, a distinct subpopulation (9% ± 1.5%; n = 14 donors) of CD34 + Lin − CD10 − CD45RA + cells in normal human bone marrow had high expression of CD62L ( Fig. 1c) . Functional screening of CD34 + Lin − fractions by assay of CFU-C demonstrated that only the CD34 + Lin − CD10 − CD62L hi population (called 'CD10 − CD62L hi cells' here) and the CD34 + Lin − CD10 + population (called 'CD10 + cells' here) were devoid of clonogenic myelo-erythroid potential ( Fig. 1d and Supplementary Table 1 ). Of note, the CD34 + Lin − CD10 − CD45RA + population with intermediate expression of CD62L had low but detectable CFU-C potential (population B, Supplementary Fig. 1b,c) , which suggested that progressive loss of multipotency correlated with increasing CD62L expression. A r t i c l e s CD10 + cells had low or undetectable expression of CD62L, and the CD34 + Lin − CD38 − population, which is enriched for HSCs and multipotent progenitors (MPPs) 21 , had intermediate expression of CD62L ( Fig. 1e and Supplementary Fig. 1b) . Notably, CD10 − CD62L hi cells did not express CD7 ( Fig. 1f ). Thus, the progenitor subset with highest CD62L expression expressed neither CD10 nor CD7, markers that have been relied on for the isolation of human lymphoid progenitors. Analysis of bone marrow from 20 different donors whose ages ranged from infancy to adulthood consistently showed the presence of CD10 − CD62L hi cells (Supplementary Fig. 2a-c ).
Lymphoid and monocyte potential of CD10 − CD62L hi cells Culture in lymphoid conditions demonstrated that the CD10 − CD62L hi population robustly generated both B cells and NK cells ( Fig. 2a) . Consistent with published studies 11 , CD10 + cells (all of which were CD19 − through depletion of lineage marker-expressing cells) generated mostly B cells with relatively weak potential to develop into NK cells. Cell output under B cell-NK cell lymphoid conditions tended to be higher in cultures initiated with CD10 − CD62L hi cells than in those initiated with CD10 + cells ( Fig. 2b) . After in vitro culture under T cell conditions, CD10 − CD62L hi cells generated cells that had the immunophenotype typical of thymocytes (expression of CD1A, CD7, CD4, CD8, CD3 and TCRαβ) 23 (Fig. 2c,d and Supplementary Fig. 3 ) and that expressed the T cell-associated genes TCF7, GATA3, DNTT and RAG1 (Supplementary Fig. 3 ), as well as CD56 + NK cells (some of which coexpressed CD8). Cell output was significantly higher in T cell cultures initiated with CD10 − CD62L hi cells than in those initiated with CD10 + cells ( Fig. 2e) .
Although we did not detect clonogenic myeloid cells by assay of CFU-C, both the CD10 + and CD10 − CD62L hi subsets were able to generate low numbers of myeloid cells when cultured on stromal layers; however, cell output from both progenitor types was significantly lower than that of HSCs-MPPs ( Fig. 2f) . Most nonlymphoid cells generated from the CD10 + and CD10 − CD62L hi populations in stromal coculture were CD14 + CD33 + monocytes-macrophages or CD209 + CD1a + dendritic cells ( Supplementary Fig. 4) ; CD66b + granulocytes were uncommon. We rarely noted erythroid differentiation in CD10 + or CD10 − CD62L hi cultures, but the production of erythroid cells was robust in cultures from CD38 − HSCs-MPPs.
The cloning efficiency of CD10 − CD62L hi cells in lymphoid cultures initiated with a single cell (~11%) and by limiting-dilution analysis (cloning efficiency, 1 cell in 5.3 cells for B cells-NK cells (95% confidence interval, 1 in 4.4-6.4), and 1 cell in 5.6 cells for T cell cultures (95% confidence interval, 1 in 4.6-6.9); Fig. 3a,b ) was similar to that of CD10 + cells (~12% from single cells). However, lineage analysis of clones demonstrated that the CD10 − CD62L hi population contained bi-potent B cell-NK cell progenitors, whereas the CD10 + population contained predominantly unipotent B cell progenitors ( Fig. 3c) . We detected myeloid cells in 86% of the clones that could be assigned a lineage in B cell-NK cell conditions ( Fig. 3d ) and in 97% of all clones assayed from T cell cultures ( Fig. 3e) . Consistent with the in vitro assays of lineage potential, intratibial transplantation of CD10 − CD62L hi progenitors into immunodeficient mice of the NSG strain (nonobese diabetic-severe combined immunodeficiency strain, deficient in the interleukin 2 (IL-2) receptor IL-2Rγ) produced rapid marrow engraftment of both myeloid and B lymphoid cells ( Fig. 3f,g and Supplementary Fig. 5 ).
Differentiation of non-self-renewing progenitors into T lymphoid cells would not be expected in this xenogeneic adult mouse model.
In summary, our functional assays showed that the CD10 − CD62L hi population had full lymphoid potential, was less skewed toward the B lineage than was the CD10 + population, and had greater potential to develop into T cells than did CD10 + population. Although the population lacked clonogenic myelo-erythroid potential, some differentiation of the CD10 − CD62L hi population into myeloid cells Week 4
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Week 8 
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A r t i c l e s (mostly monocytes-macrophages and dendritic cells) was induced in stromal cocultures and in short-term engraftment assays. However, its myeloid potential was significantly lower than that of HSCs-MPPs, and erythroid potential was absent.
Differentiation stages of HSCs and lymphoid progenitors
Given the lineage potential shown in the functional studies reported above, we next explored the stages of differentiation of the CD10 − CD62L hi and CD10 + populations compared with those of the npg most primitive CD34 + Lin − CD38 − HSC-MPP population (called 'CD38 − cells' here). Expression of the differentiation marker CD38 increased progressively from the CD34 + CD38 − population to the CD10 − CD62L hi population and was maximal in the CD10 + population (n = 14 donors; Fig. 4a ). Expression of the stem cell-associated receptors c-Kit, Flt3, integrin α 6 (CD49F) and Prom-1 (CD133) was similar in CD38 − and CD10 − CD62L hi populations but was downregulated in CD10 + cells; Thy-1 (CD90) had its highest expression on CD38 − cells. HLA-DR was upregulated in both CD10 − CD62L hi and CD10 + progenitors (Fig. 4a) . After 1 week in lymphoid culture, CD10 + cells differentiated and lost expression of the adhesion molecule CD34 faster than did CD10 − CD62L hi cells (Fig. 4b) . In addition, CD10 − CD62L hi cells were able to generate CD34 + CD10 + cells in vitro (Fig. 4b) , which suggested that CD10 − CD62L hi cells were precursors of the CD10 + population. Principal-component analysis of global gene-expression data from microarray analysis of three different bone marrow samples also placed the CD10 − CD62L hi progenitors in an intermediate position between the CD38 − HSCs-MPPs and the CD10 + progenitors (Fig. 4c) .
Gene expression of CD10 − CD62L hi progenitors clustered hierarchically with CD38 − HSCs-MPPs rather than with CD10 + progenitors (Supplementary Fig. 6a ). By pairwise comparison with HSCs-MPPs, similar numbers of genes were upregulated in CD10 − CD62L hi and CD10 + populations; approximately half of those upregulated genes were common to both progenitor types (Supplementary Fig. 6b ). More than twice as many genes were downregulated in the CD10 + population than were downregulated in the CD10 − CD62L hi population, and most downregulated genes in CD10 − CD62L hi cells were also downregulated in CD10 + cells (Supplementary Fig. 6b) . Thus, the differentiation of HSCs-MPPs involved many shared molecular pathways, but additional transcriptional modulation seemed to occur after the CD10 − CD62L hi stage during the generation of CD10 + cells.
Downregulation of HSC-associated genes in CD10 − CD62L hi cells
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Cluster 6   MYCT1  GATA2  GATA3  PRDM16  TAL1  HOXB3  HOXB4  HOXB5  HOXB6  PCGF2  PHC2  SCML4  ZBTB16   HOXA3  MEIS1  CEBPB  PBX1  HMGA2  FOSL1  FOSL2  FOSB   HOXA5  HOXA7  HOXA9  HOXA10   CEBPD   CEBPA   BCL6  BCL2  RUNX1  RUNX2  RUNX3   HDAC3  HDAC4   PHF19   EZH2  SUZ12  EED  CBX4  MEF2A   TCF3  LEF1  ZHX2  FOXO1  PAX5  MTF2 npg A r t i c l e s relationships among the CD38 − , CD10 − CD62L hi and CD10 + populations. All genes included in the heat maps had a difference in expression of at least twofold in one population relative to their expression in the other two populations (P < 0.05 (moderated t-statistics)) and belonged to one of six different expression patterns (clusters 1-6; Fig. 5a,b) . Genes encoding known HSC-related transcription factors (TAL1, GATA2 and PRDM16) were significantly downregulated in both CD10 − CD62L hi cells and CD10 + cells relative to their expression in the CD38 − population (cluster 1; Fig. 5a ). Genes of the HOXB family were also downregulated during the transition from the CD38 − HSC-MPP stage to the CD10 − CD62L hi LMPP stage with no further significant change at the CD10 + stage (cluster 1; Fig. 5a ). In contrast, expression of genes of the HOXA family decreased later in differentiation at the CD10 + progenitor stage (clusters 2 and 3; Fig. 5a ). We noted reciprocal patterns of expression for members of the polycomb repressive complexes PRC1 (encoded by PCGF2, PHC2, and SCML4) and PRC2 (encoded by SUZ12, EZH2 and EED) 24 (clusters 1 and 5, respectively; Fig. 5a) . These analyses identified a highly coordinated program of transcriptional regulation as HSCs lost multipotency, became lymphoid primed and then committed to B lymphopoiesis.
Lymphoid-differentiation stages of CD10-CD62L hi and CD10 + cells
Analysis of genes upregulated only in the CD10 − CD62L hi population (cluster 4; Fig. 5b ) showed a profile consistent with the dual lymphoid and monocyte potential of this population. Specifically, genes associated with T cell and NK cell lineages (CD2 and CD3E) 14, [25] [26] [27] and genes encoding lymphoid cytokine receptors (IL2RG, IL10RA, IL10RB, IL17RA and IFNGR1) were upregulated, as were myeloid cell-associated genes (MPO, CSF1R and CSF2R; Fig. 5b) . Consistent with the cell surface expression of Flt3, FLT3 was expressed in both HSCs-MPPs and CD10 − CD62L hi cells but not in CD10 + cells (cluster 3; Fig. 5b) . Consistent with the B cell-skewed differentiation potential of the CD10 + population, genes known to be expressed specifically during commitment to the B cell lineage (EBF1, PAX5, IL7R, CD79A, CD79B, VPREB1, VPREB3, CD19, CD22, CD24 and CD27) had high expression in CD10 + cells (cluster 6; Fig. 5a-c) . Notably, none of those B cell-specific genes were expressed in either CD34 + CD38 − cells or CD10 − CD62L hi cells. Detailed analysis by quantitative PCR showed that although expression of genes encoding molecules essential for lymphoid commitment was highest in CD10 + cells, upregulation of certain genes encoding molecules of early lymphoid differentiation began at the CD10 − CD62L hi stage. Expression of TCF3 (which encodes the transcription factor E2A) increased 2.1-fold during the transition from CD38 − cell to CD10 − CD62L hi cell and increased 4.4-fold in the transition from CD10 − CD62L hi cell to CD10 + cell (Fig. 5c) . Similarly, DNTT expression increased 8.0-fold during the transition from CD38 − cell to CD10 − CD62L hi cell and increased 12.0-fold in the transition from CD10 − CD62L hi cell to CD10 + cell (Fig. 5c) . In contrast, RAG1 expression was limited to CD10 + cells (Fig. 5c) , which demonstrated that the mechanisms of DNA rearrangement for genes encoding T cell antigen receptors and immunoglobulins were not fully initiated in the CD10 − CD62L hi population.
To investigate further the degree of heterogeneity of the three populations, we assayed the expression of key genes in single cells (Fig. 5d) . These analyses showed that the HSC genes TAL1 (which encodes the transcription factor SCL (Tal-1)) and MPL (which encodes the thrombopoietin receptor) were expressed exclusively in CD38 − cells, and expression of RAG1 and PAX5 (which encodes the transcription factor Pax5) was limited to CD10 + cells. We detected expression of TCF3 in a similar percentage of CD10 − CD62L hi and CD10 + cells. Detectable FLT3 expression in single cells was limited almost exclusively to the CD10 − CD62L hi population (Fig. 5d) . Thus, the CD38 − HSC-MPP, CD10 − CD62L hi and CD10 + populations had distinct molecular profiles, consistent with their functional 'readout' in vitro. Whereas the CD10 + population was committed to B lymphopoiesis, the CD10 − CD62L hi population included cells with evidence of npg early lymphoid priming but no expression of genes associated with commitment to the B cell lineage (Supplementary Fig. 7 ).
CD62L and ligand expression in human thymus
We analyzed by flow cytometry and gene expression the coexpression of receptor-ligand pairs that have been reported before in mouse studies as being important in the homing of cells to and settling of cells in the thymus [28] [29] [30] . Expression of the chemokine receptor CXCR4 was similar in CD10 − CD62L hi and CD10 + populations (Fig. 6a) . However, PSGL-1 (the ligand for P-selectin) and the activation and memory marker CD44 both had higher expression in CD10 − CD62L hi cells than in CD10 + cells (Fig. 6a) . In addition, the gene encoding the chemokine receptor CCR7, which is expressed on mouse early thymic progenitors and mediates the migration of early thymocytes [28] [29] [30] , was significantly upregulated in the CD10 − CD62L hi population relative to its expression in either CD10 + cells or the CD38 − population (Fig. 6b) .
We noted no consistent differences between the populations in their expression of the chemokine CCR9 (data not shown). We next examined the expression of CD62L in progenitor populations from human thymus. CD62L expression was higher in CD34 + thymic progenitors than in the more mature CD34 − thymocytes (which represent >95% of all thymocytes; Fig. 6c ). After further fractionation of the CD34 + thymocyte population, we found that most CD62L-expressing cells were in the CD34 + CD1a − subset rather than the more mature CD34 + CD1a + subset (Fig. 6c) . MECA-79 detects a carbohydrate epitope found on the family of CD62L ligands known as 'peripheral node addressins' 31 . We detected staining of MECA-79 in the thymic vasculature specifically in a subset of P-selectinpositive endothelial cells at the cortico-medullary junction of the thymus, the site of entry of marrow-derived precursors into the thymus (Fig. 6d-j) ; this suggested a possible role for CD62L in homing to the human thymus.
DISCUSSION
Our studies presented here have demonstrated that 'lymphoid priming' in human bone marrow began before the onset of CD10 expression in a subset of CD34 + progenitors with high expression of the homing molecule CD62L. Several pieces of evidence suggested that the CD10 − CD62L hi population was a precursor of the more B cellrestricted CD10 + stage of lymphopoiesis. First, it is widely assumed that all human B cell differentiation passes through a CD10 + progenitor stage, and cultures initiated with CD10 − CD62L hi cells were able to generate CD10 + progenitors before differentiating into CD19 + B cells. In addition, although the CD10 − CD62L hi population had greater NK cell potential, the number of B cells generated in culture was at least equivalent to that generated in cultures of CD10 + cells. The patterns of the expression of genes and cell-surface antigens were also consistent with a model that positions the CD10 − CD62L hi population before CD10 expression.
A published study has described a CD10 + subset in a CD34 + CD38 neg−lo population with lymphoid, monocytic and dendritic cell potential but no erythroid potential 21 . However, this CD10 + 'multilymphoid progenitor' also expressed the B cell-specific gene PAX5. Notably, the strategy for the isolation of those multilymphoid progenitors included cells with intermediate expression of CD38, similar to expression in the CD10 − CD62L hi population and higher than that in the most primitive HSC fraction. We propose that lymphoid priming begins with upregulation of CD38 (relative to its expression in HSCs) and that B cell commitment is initiated with the onset of CD10 expression and further upregulation of CD38 expression.
Most human hematopoietic studies have used UCB, largely because this source of human cells is more readily accessible than is bone marrow. The proliferative output of bone marrow progenitors is much lower than that of their immunophenotypic homologs in UCB 7, 17, [32] [33] [34] or that of HSCs from either source 35 , which makes in vivo assessment of rare, non-self-renewing bone marrow progenitor populations difficult and sometimes unfeasible. However, UCB does not represent steady-state postnatal hematopoiesis, and substantial differences between progenitors from UCB and bone marrow are known to exist for both immunophenotype and function 6 . Notably, the functional and molecular profiles of CD10 − CD62L hi bone marrow progenitors (which do not express CD7) are similar to those of CD34 + CD38 − CD7 + UCB progenitors 20 . Moreover, we found that the CD10 − CD62L hi immunophenotype described here was less reliable for the identification of a pure lymphoid-primed population in UCB than in bone marrow; a distinct CD62L hi population was difficult to detect in UCB, and CD34 + Lin − CD10 − CD45RA + CD62L + cell populations in UCB included small but readily detectable numbers of CFU-C (Q.-L.H. and G.M.C., unpublished data). The differences in the lineage potentials of cells with similar immunophenotypes in UCB and bone marrow, as well as the intrinsic functional differences that would be expected between cells that are detected transiently in the postnatal circulation and those that are generated throughout life in the bone marrow microenvironment, highlight the critical need for studies that focus on human bone marrow.
Considerable data have been generated in mouse studies to both support and challenge the classic idea that the lymphoid and myeloerythroid pathways emerge separately from a multipotent progenitor stage [1] [2] [3] [4] 36 . The 'lymphoid-primed' LMPPs in mouse bone marrow retained full lymphoid and some myeloid potential but had lost erythro-megakaryocytic potential, whereas common lymphoid progenitors (CLPs) represented a more mature, lymphoid-restricted progenitor population. Cell surface expression of Flt3 has been used to isolate LMPPs from a subpopulation of c-Kit + Lin − Sca-1 + cells in mouse bone marrow 2 , and the IL-7 receptor IL-7Rα is used to define mouse CLPs in the c-Kit − Lin − Sca-1 lo population 1 . Given our functional and molecular data, the CD10 − CD62L hi human bone marrow progenitor seems most similar to the mouse LMPPs, and the CD10 + progenitor is more analogous to the mouse CLPs. However, despite upregulation of FLT3 at the transcriptional level, cell-surface expression of Flt3 has not been found to be useful as a marker for discriminating between human HSCs and LMPPs 21 (and reported here). Notably, studies have reported that upregulation of CD62L expression in c-Kit + Lin − Sca-1 + mouse bone marrow cells correlates with high expression of Flt3 and loss of erythroid and megakaryocyte potential, which suggests that CD62L expression might be used as an alternative marker for discriminating between mouse multipotent progenitors and LMPPs 14 .
The myeloid output of the CD10 − CD62L hi population consisted mostly of monocyte-macrophage and dendritic cells. The absence of clonogenic myeloid-erythroid potential in assays of CFU-C suggested that the CD10 − CD62L hi population does not represent a precursor of the main myelo-erythroid pathways initiated by common myeloid progenitors and granulocyte-macrophage progenitors. Instead, we favor the proposal that the CD10 − CD62L hi cells are 'lymphoidprimed' progenitors that precede CD10 expression and are able to generate limited numbers of monocytes-macrophages and dendritic cells. This type of residual myeloid and dendritic potential has been reported for even more lymphoid-committed progenitors 10, 17, 21 . A published paper has noted that mouse IL-7Rα + CLPs, despite their complete lack of either CFU activity or in vivo myeloid potential, npg A r t i c l e s can generate myeloid cells in stromal cocultures, which suggests that myeloid differentiation may be an alternative pathway in certain in vitro conditions 5 . Nonetheless, it is clear that the capacity for myeloid differentiation in vitro progressively wanes as lymphoid commitment proceeds and that this residual, mostly monocytic potential is retained after erythroid potential is lost.
We noted both differences and similarities between the CD10 − CD62L hi cells and mouse LMPPs in their gene expression 2, 36 . In both mouse LMPPs and human CD10 − CD62L hi cells, genes encoding the transcription factor Tal-1 and the cytokine receptor MPL are substantially downregulated relative to their expression in HSCs, whereas expression of the gene encoding c-Kit is retained 36, 37 . Expression of the gene encoding E2A, which is essential for the development of mouse LMPPs 38 , was also upregulated during generation of the CD10 − CD62L hi population from HSCs-MPPs, but B cellspecific genes such as EBF1 and PAX5 were not. In contrast, components of the molecular machinery required for DNA recombination seem to have high expression in mouse LMPPs 36 , but in our human studies, RAG1 and RAG2 were expressed at the CD10 + stage and DNTT expression was significantly higher in CD10 + cells than in CD10 − CD62L hi cells.
The identification of a lymphoid-primed progenitor that may be a precursor of the CD10 + 'CLP' 10 raises the question of whether CD10 − CD62L hi cells are recruited to the thymus to initiate T cell differentiation. Controversy about the identity of precursors that seed the mouse thymus has continued for over a decade, and it seems likely that more than one type of bone marrow progenitor may be able to initiate thymopoiesis. Experimental restrictions make it impossible to definitively prove the identity of the bone marrow precursors that normally seed the human thymus. The CD10 + CD24 − population in bone marrow possibly represents a lymphoid progenitor that seeds the human thymus, given the finding of a similar immunophenotypic subset among human thymocytes 12 . The thymocyte data presented here have provided evidence that CD10 − CD62L hi cells may be an additional or alternative thymic precursor population. It should be noted that although CD62L expression was highest on CD34 + CD1a − progenitors, CD10 − CD62L hi bone marrow cells are not precursors of the most primitive (CD7 − ) subset of CD34 + CD1a − thymocytes. CD34 + CD1a − CD7 − thymocytes have high myeloid and erythroid potential in clonogenic assays 39 and do not express CD62L. It is not clear at this time whether CD62L becomes upregulated as CD34 + CD1a − CD7 − MPPs differentiate into CD34 + CD1a − CD7 + thymocytes or whether CD7 is rapidly upregulated when CD7 − CD62L hi LMPPs engage with the thymic microenvironment. PSGL-1-P-selectin interactions are critical mediators of homing to mouse thymus 40 . As PSGL-1 had abundant expression on both HSCs-MPPs and CD10 − CD62L hi bone marrow cells, it is possible that homing to human thymus involves the same mechanism. However, the high expression of CD62L in the primitive CD34 + CD1a − thymocyte population and the endothelial expression of CD62L ligands in the human thymus, specifically in the corticomedullary region, raise the possibility that in addition to being involved in the homing of lymphocytes to peripheral lymphoid organs, CD62L may have a role in the homing of progenitors to human thymus. We have noted expression of CD62L in a subset of CD34 + Lin − CD10 − cells (but not CD34 + CD10 + cells) in mobilized peripheral blood (data not shown), but the physiological relevance and lineage potential of this mobilized population is as yet unclear. Of note, although interactions with CD62L have not been described in homing to mouse thymus, CD62L expression has been used to identify a population of mouse bone marrow progenitors that efficiently and rapidly reconstitute the mouse thymus after transplantation 15, 16 , and a population of c-Kit + Lin − Sca-1 + CD62L + RAG-1 − progenitors is present in both mouse bone marrow and mouse thymus 16 .
The reliance on CD10 expression as a marker of lymphoid commitment in previous studies of hematopoietic progenitors in human bone marrow has until now meant that states of differentiation could be compared only between multipotent progenitors and progenitors committed to the B cell lineage. The identification of a progenitor in human bone marrow primed for full lymphoid differentiation, and at a stage before B cell commitment, will now permit delineation of the molecular regulation of the first stages of lymphoid commitment in human hematopoiesis. It will also allow understanding of how these processes are affected during aberrant hematopoiesis in disease states.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE35685.
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